MS is divided into four subtypes: clinically isolated syndrome, relapsing remitting, primary and secondary progressive MS and are used to guide the timing and choice of treatments. However, these subtypes are based on observed symptoms, such as relapses and disability which can be difficult to measure and may not reflect the underlying biology driving the course of someone’s MS.
Researchers wanted to find out if there are hidden patterns in MRI brain scans taken over time that would better identify biological differences in MS activity and detect progression earlier.
The international team used MRI scans previously taken in clinical trials involving 6322 people with MS. Data was extracted from the scans and machine learning (artificial intelligence) used to identify subgroups with similar patterns of change in brain structures over time. Results from the initial findings were tested against a second set of MRI scans from 3,068 people with MS. Read on.
If anyone has any spare plants for potting into a tub for the centre please let me know? We have a square planter by the ramp, it’s a bit tatty but with some nice summer flowers in it, it might brighten the front up a bit.
In light of the fact that most people have now had both their jabs and infection rates are greatly reduced we will go back to keeping masks at the centre and asking you to clean your mask yourself with anti-bacterial wipes and then placing it in a bag.
Please then pass your bag to an operator to put away.
Over the last few years, the MS Society has been asking for feedback on how they can improve our forum. This is to make sure they can give you the best experience possible.
Thanks to your feedback, they have been able to create the perfect space to support, share, and connect with like-minded people in the MS community. Read on.
There are now over a dozen licensed disease modifying therapies (DMTs) for people with relapsing MS, and some emerging for early active progressive MS. But to help people at every stage of MS, we need to stop MS from progressing.
Currently, all available DMTs target the immune system. To truly stop MS getting worse, we also need treatments that protect nerves from damage and repair lost myelin.
Now, after years of planning, our ambition to speed up clinical trials for progressive MS is becoming a reality. With recruitment starting later this year, Octopus will provide a smarter way of testing potential MS drugs. This could deliver life-changing new treatments up to three times faster. Read on.
